Neurocrine Biosciences (NBIX) has begun registering prospective patients for a phase 3 trial to evaluate the efficacy, safety and tolerability of its NBI-1117568 drug candidate to treat adults with a primary diagnosis of schizophrenia, the company said on Wednesday morning.
The new, doubled-blinded study is expected to enroll around 280 patients who are experiencing an acute exacerbation or relapse of schizophrenia symptoms and will receive a once-daily 20 milligram dose of the investigational oral muscarinic M4 selective orthosteric agonist.
The upcoming trial will have a primary endpoint of the reduction from baseline as measured by the Positive and Negative Syndrome Scale and a key secondary endpoint of improvement on the Clinical Global Impression of Severity scale.
During phase 2 testing, top-line data reported last August showed clinically meaningful and statistically significant reduction from baseline on the PANSS total score after six weeks compared with patients treated with a placebo.
Neurocrine shares were little changed during recent Wednesday trading.
Price: 106.85, Change: -0.39, Percent Change: -0.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.